Study shows no mitotane needed for patients with low risk of recurrence of adrenocortical carcinoma

In 2007, the teams of Massimo Terzolo and Martin Fassnacht published a study in the New England Journal of Medicine that provided evidence for the efficacy of mitotane in the prevention of recurrence in adrenocortical carcinoma. This study established the drug worldwide as a standard therapy for relapse prophylaxis after surgical removal of the tumor, regardless of risk factors that were still unknown at the time.